atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The company has confirmed that the deceased are 39
Surpassing 1,000 Company Owned Company Operated stores
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
A triple-action Formula for comprehensive respiratory relief
Subscribe To Our Newsletter & Stay Updated